Artigos de revistas sobre o tema "Oncohistone H3.3 K27M"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Oncohistone H3.3 K27M".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Liu, Ilon, Jiang Li, Daeun Jeong, Olivia A. Hack, McKenzie Shaw, Bernhard Englinger, Byron Avihai et al. "EPCO-06. AGE- AND REGION-SPECIFIC MULTI-OMIC CHARACTERIZATION OF H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA". Neuro-Oncology 23, Supplement_6 (2 de novembro de 2021): vi2. http://dx.doi.org/10.1093/neuonc/noab196.005.
Texto completo da fonteLiu, I., L. Jiang, E. Samuelsson, S. Marco Salas, O. Hack, D. Jeong, M. Shaw et al. "JS04.6.A The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location". Neuro-Oncology 24, Supplement_2 (1 de setembro de 2022): ii7. http://dx.doi.org/10.1093/neuonc/noac174.021.
Texto completo da fonteLiu, Ilon, Li Jiang, Erik Samuelsson, Sergio Marco Salas, Alexander Beck, Olivia Hack, Daeun Jeong et al. "DIPG-08. THE LANDSCAPE OF TUMOR CELL STATES AND SPATIAL ORGANIZATION IN H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA ACROSS AGE AND LOCATION". Neuro-Oncology 25, Supplement_1 (1 de junho de 2023): i14. http://dx.doi.org/10.1093/neuonc/noad073.055.
Texto completo da fonteHübner, Jens-Martin, Torsten Müller, Dimitris N. Papageorgiou, Monika Mauermann, Jeroen Krijgsveld, Robert B. Russell, David W. Ellison, Stefan M. Pfister, Kristian W. Pajtler e Marcel Kool. "EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma". Neuro-Oncology 21, n.º 7 (29 de abril de 2019): 878–89. http://dx.doi.org/10.1093/neuonc/noz058.
Texto completo da fonteLiapodimitri, Athanasia, Kayleigh Lunsford, Ashley R. Tetens, Jordyn Craig-Schwartz, Farhad Vesuna, Venu Raman e Michael A. Koldobskiy. "DIPG-64. UNRAVELING H3K27M INTERACTIONS IN DIFFUSE MIDLINE GLIOMA". Neuro-Oncology 26, Supplement_4 (18 de junho de 2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.117.
Texto completo da fonteAndrade, Augusto Faria, Danai Topouza, Michael McNicholas, Eduardo G. Gonzalez Santiago, Antonella De Cola, Arne Gehlhaar, Selin Jessa et al. "TMIC-04. IMMUNE PROFILING OF PEDIATRIC ONCOHISTONE GLIOMAS REVEALS DIVERSE MYELOID POPULATIONS AND TUMOR-PROMOTING BEHAVIORS". Neuro-Oncology 25, Supplement_5 (1 de novembro de 2023): v278. http://dx.doi.org/10.1093/neuonc/noad179.1070.
Texto completo da fonteBudd, Kaitlin, Chang-Hyuk Kwon, Lawryn H. Kasper, Christopher Roberts, Jordan Roach, Jennifer Ocasio-Adorno, Jon D. Larson e Suzanne J. Baker. "Abstract IA007: Transforming chromatin: Oncohistone mutations in pediatric high-grade glioma". Cancer Research 82, n.º 23_Supplement_2 (1 de dezembro de 2022): IA007. http://dx.doi.org/10.1158/1538-7445.cancepi22-ia007.
Texto completo da fonteKida, Jun-ichiro, Takayuki Tsujioka, Shin-ichiro Suemori, Shuichiro Okamoto, Kanae Sakakibara, Takahiro Yamauchi, Akira Kitanaka, Yumi Tohyama e Kaoru Tohyama. "Malignant Progression of an MDS-Derived Cell Line Serves As an in Vitro Model for the Leukemic Evolution of MDS". Blood 132, Supplement 1 (29 de novembro de 2018): 5501. http://dx.doi.org/10.1182/blood-2018-99-110583.
Texto completo da fonteHohm, Annika, Michael Karremann, Gerrit H. Gielen, Torsten Pietsch, Monika Warmuth-Metz, Lindsey A. Vandergrift, Brigitte Bison et al. "Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma". Clinical Neuroradiology 32, n.º 1 (17 de dezembro de 2021): 249–58. http://dx.doi.org/10.1007/s00062-021-01120-3.
Texto completo da fonteZhang, Peng, Tiantian Han, Yi Lu, Weijie Sun, Wanglong Deng, Guanghua Lu, Didi Guo, Xiaomin Li e Fanfeng Bu. "Molecular characteristics of H3 K27M mutation gliomas in Chinese adults." Journal of Clinical Oncology 39, n.º 15_suppl (20 de maio de 2021): e14018-e14018. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14018.
Texto completo da fonteShema, Efrat. "Abstract PR006: Single-molecule and single-cell epigenetics: Decoding the epigenome for cancer research and diagnostics". Cancer Research 82, n.º 23_Supplement_2 (1 de dezembro de 2022): PR006. http://dx.doi.org/10.1158/1538-7445.cancepi22-pr006.
Texto completo da fonteMorita, Shuhei, Masayuki Nitta, Yoshihiro Muragaki, Takashi Komori, Kenta Masui, Takashi Maruyama, Koichi Ichimura et al. "Brainstem pilocytic astrocytoma with H3 K27M mutation: case report". Journal of Neurosurgery 129, n.º 3 (setembro de 2018): 593–97. http://dx.doi.org/10.3171/2017.4.jns162443.
Texto completo da fonteOdia, Yazmin, Ashley Love Sumrall, Timothy Francis Cloughesy, Phioanh Leia Leia Nghiemphu, Matthew David Hall, Doured Daghistani, Minesh P. Mehta et al. "Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas." Journal of Clinical Oncology 39, n.º 15_suppl (20 de maio de 2021): e14037-e14037. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14037.
Texto completo da fonteOdia, Yazmin, Ashley Sumrall, Timothy Cloughesy, Phioanh Nghiemphu, Matthew Hall, Doured Daghistani, Minesh Mehta et al. "CTNI-27. SINGLE AGENT ACTIVITY OF ONC201 IN NON-MIDLINE H3 K27M-MUTANT DIFFUSE GLIOMAS". Neuro-Oncology 23, Supplement_6 (2 de novembro de 2021): vi65. http://dx.doi.org/10.1093/neuonc/noab196.252.
Texto completo da fonteGardner, Sharon L., Carl Johannes Koschmann, Rohinton Tarapore, Jeffrey C. Allen, Wafik Tharwat Zaky, Yazmin Odia, Matthew Hall et al. "ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG." Journal of Clinical Oncology 38, n.º 15_suppl (20 de maio de 2020): 3619. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3619.
Texto completo da fonteKawakibi, Abed Rahman, Rohinton S. Tarapore, Sharon Gardner, Andrew Chi, Sylvia Kurz, Patrick Y. Wen, Isabel Arrillaga-Romany et al. "HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA". Neuro-Oncology 22, Supplement_3 (1 de dezembro de 2020): iii347. http://dx.doi.org/10.1093/neuonc/noaa222.305.
Texto completo da fonteKawakibi, Abed Rahman, Rohinton Tarapore, Sharon L. Gardner, Sylvia Christine Kurz, Patrick Y. Wen, Isabel Arrillaga-Romany, Tracy Batchelor et al. "Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma." Journal of Clinical Oncology 38, n.º 15_suppl (20 de maio de 2020): 3617. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3617.
Texto completo da fonteHall, Matthew D., Yazmin Odia, Joshua E. Allen, Rohinton Tarapore, Ziad Khatib, Toba N. Niazi, Doured Daghistani et al. "First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report". Journal of Neurosurgery: Pediatrics 23, n.º 6 (junho de 2019): 719–25. http://dx.doi.org/10.3171/2019.2.peds18480.
Texto completo da fonteSchulte, Jessica, Robin Buerki, Sarah Lapointe, Annette Molinaro, Yalan Zhang, Javier Villanueva-Meyer, Arie Perry et al. "PATH-30. CLINICAL AND GENETIC CHARACTERISTICS OF HISTONE H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IN ADULTS". Neuro-Oncology 22, Supplement_2 (novembro de 2020): ii170—ii171. http://dx.doi.org/10.1093/neuonc/noaa215.711.
Texto completo da fonteLiu, Ilon, Li Jiang, Erik R. Samuelsson, Sergio Marco Salas, Alexander Beck, Olivia A. Hack, Daeun Jeong et al. "The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location". Nature Genetics 54, n.º 12 (dezembro de 2022): 1881–94. http://dx.doi.org/10.1038/s41588-022-01236-3.
Texto completo da fonteRahman Kawakibi, Abed, Sharon Gardner, Andrew Chi, Sylvia Kurz, Patrick Wen, Isabel Arrillaga-Romany, Tracy Batchelor et al. "PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA". Neuro-Oncology 21, Supplement_6 (novembro de 2019): vi186. http://dx.doi.org/10.1093/neuonc/noz175.773.
Texto completo da fonteQiu, Tianming, Apisara Chanchotisatien, Zhiyong Qin, Jinsong Wu, Zunguo Du, Xialing Zhang, Fangyuan Gong, Zhenwei Yao e Shuguang Chu. "Imaging characteristics of adult H3 K27M-mutant gliomas". Journal of Neurosurgery 133, n.º 6 (dezembro de 2020): 1662–70. http://dx.doi.org/10.3171/2019.9.jns191920.
Texto completo da fonteChen, Xueling, Ling Zhong, Jianwen Lin e Jian Yu. "A rare case of adult diffuse midline glioma with H3 K27M mutant in the prepontine cistern". Journal of International Medical Research 49, n.º 1 (janeiro de 2021): 030006052098126. http://dx.doi.org/10.1177/0300060520981266.
Texto completo da fonteArrillaga-Romany, Isabel, Andrew Lassman, Susan McGovern, Sabine Mueller, L. Burt Nabors, Martin van den Bent, Michael Vogelbaum et al. "RTID-01. ONC108: A RANDOMIZED PHASE 3 STUDY OF ONC201 IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA". Neuro-Oncology 24, Supplement_7 (1 de novembro de 2022): vii249. http://dx.doi.org/10.1093/neuonc/noac209.961.
Texto completo da fonteArrillaga-Romany, I., A. Lassman, S. L. McGovern, S. Mueller, L. B. Nabors, M. van den Bent, M. Vogelbaum et al. "P11.46.A ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA". Neuro-Oncology 25, Supplement_2 (1 de setembro de 2023): ii84. http://dx.doi.org/10.1093/neuonc/noad137.280.
Texto completo da fonteArrillaga-Romany, Isabel, Andrew Lassman, Susan McGovern, Sabine Mueller, Louis Burt Nabors, Martin van den Bent, Michael Vogelbaum et al. "TIPS-08 ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA". Neuro-Oncology Advances 5, Supplement_3 (1 de agosto de 2023): iii35—iii36. http://dx.doi.org/10.1093/noajnl/vdad070.139.
Texto completo da fonteDeMasters, B. K., Samuel Guzman e David Ormond. "PATH-18. MORE UNUSUAL FEATURES IN H3 K27M-MUTANT GLIOMAS". Neuro-Oncology 25, Supplement_5 (1 de novembro de 2023): v171. http://dx.doi.org/10.1093/neuonc/noad179.0648.
Texto completo da fonteArrillaga-Romany, Isabel, Andrew Lassman, Susan L. McGovern, Sabine Mueller, Louis B. Nabors, Martin van den Bent, Michael Vogelbaum et al. "Abstract CT060: ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma". Cancer Research 83, n.º 8_Supplement (14 de abril de 2023): CT060. http://dx.doi.org/10.1158/1538-7445.am2023-ct060.
Texto completo da fonteGardner, Sharon, Rohinton Tarapore, Jeffrey Allen, Wafik Zaky, Yazmin Odia, Matthew Hall, Doured Daghistani et al. "DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG". Neuro-Oncology 22, Supplement_3 (1 de dezembro de 2020): iii297. http://dx.doi.org/10.1093/neuonc/noaa222.097.
Texto completo da fonteGardner, Sharon L., Jeffrey C. Allen, Wafik Tharwat Zaky, Yazmin Odia, Doured Daghistani, Ziad Khatib, Carl Johannes Koschmann et al. "ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma." Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): 10046. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10046.
Texto completo da fonteOdia, Yazmin, Carl Johannes Koschmann, Rohinton Tarapore, Jeffrey Allen, Wafik Tharwat Zaky, Matthew David Hall, Doured Daghistani et al. "Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junho de 2022): TPS2082. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps2082.
Texto completo da fonteLiu, Ilon, Jiang Li, Erik Samuelsson, Sergio Marco Salas, Alexander Beck, Olivia Hack, Daeun Jeong et al. "EPCO-21. THE SPATIAL ORGANIZATION OF H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA". Neuro-Oncology 24, Supplement_7 (1 de novembro de 2022): vii120. http://dx.doi.org/10.1093/neuonc/noac209.456.
Texto completo da fonteJia, Deze, Yi Lu, Xiaomin Li, Tiantian Han, Wanglong Deng, Fanfeng Bu e Guanghua Lu. "Comparison of next-generation sequencing and FISH/IHC for molecular classification in glioma." Journal of Clinical Oncology 39, n.º 15_suppl (20 de maio de 2021): e14021-e14021. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14021.
Texto completo da fonteOdia, Yazmin, Carl Koschmann, Rohinton Tarapore, Jeffrey Allen, Matthew Hall, Doured Daghistani, Ziad Khatib et al. "SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA". Neuro-Oncology Advances 4, Supplement_1 (1 de agosto de 2022): i22. http://dx.doi.org/10.1093/noajnl/vdac078.086.
Texto completo da fonteArrillaga-Romany, Isabel, Sylvia Kurz, Ashley Sumrall, Nicholas Butowski, Rebecca Harrison, John DeGroot, Andrew Chi et al. "ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA". Neuro-Oncology 21, Supplement_6 (novembro de 2019): vi20—vi21. http://dx.doi.org/10.1093/neuonc/noz175.077.
Texto completo da fonteKurz, Sylvia Christine, Rohinton Tarapore, Yazmin Odia, Nicholas A. Butowski, Carl Johannes Koschmann, Dolly Aguilera, Tobey J. MacDonald et al. "Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma." Journal of Clinical Oncology 38, n.º 15_suppl (20 de maio de 2020): 2563. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2563.
Texto completo da fonteArrillaga-Romany, Isabel, Sylvia Christine Kurz, Rohinton Tarapore, Ashley Sumrall, Nicholas A. Butowski, Rebecca A. Harrison, John Frederick De Groot et al. "Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma." Journal of Clinical Oncology 38, n.º 15_suppl (20 de maio de 2020): 3615. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3615.
Texto completo da fonteGessi, Marco, David Capper, Felix Sahm, Kristin Huang, Andreas von Deimling, Stephan Tippelt, Gudrun Fleischhack et al. "Evidence of H3 K27M mutations in posterior fossa ependymomas". Acta Neuropathologica 132, n.º 4 (18 de agosto de 2016): 635–37. http://dx.doi.org/10.1007/s00401-016-1608-3.
Texto completo da fonteSchniederjan, Matthew J., Cahil Potnis, Varshini Vasudevaraja, Catherine D. Moser, Bethany Watson, Matija Snuderl, Tobey MacDonald e Beverly B. Rogers. "DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines". Children 11, n.º 4 (20 de abril de 2024): 492. http://dx.doi.org/10.3390/children11040492.
Texto completo da fonteDiaz, Maria, Carlos Eduardo Silva Correia, Andrew Lin, Alexandra Miller e Elena Pentsova. "PATH-04. LEPTOMENINGEAL DISEASE IN PATIENTS WITH HISTONE-MUTANT GLIOMAS". Neuro-Oncology 23, Supplement_6 (2 de novembro de 2021): vi115. http://dx.doi.org/10.1093/neuonc/noab196.457.
Texto completo da fontePorter, William, Joshua Sulman, Katie Foot, Ruman Rahman, Richard Grundy, Robert Layfield e Farhana Haque. "HGG-47. Comparative analysis of the Histone H3 mutant protein interactome landscape in paediatric high-grade gliomas". Neuro-Oncology 24, Supplement_1 (1 de junho de 2022): i71—i72. http://dx.doi.org/10.1093/neuonc/noac079.262.
Texto completo da fonteArrillaga-Romany, Isabel, Sylvia Kurz, Rohinton S. Tarapore, Ashley Sumrall, Nicholas Butowski, Rebecca Harrison, John de Groot et al. "CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA". Neuro-Oncology 22, Supplement_2 (novembro de 2020): ii50—ii51. http://dx.doi.org/10.1093/neuonc/noaa215.204.
Texto completo da fonteHaque, Farhana. "Comparative Analysis of the Histone H3 Mutant Protein Interactome Landscape in Paediatric High-Grade Gliomas". Neuro-Oncology 24, Supplement_4 (1 de outubro de 2022): iv4. http://dx.doi.org/10.1093/neuonc/noac200.016.
Texto completo da fonteBalakrishnan, Samantha, Ivan Carabenciov, Michael Ruff, Joon Uhm e Sani Kizilbash. "RARE-37. TREATMENT OF H3K27M MUTANT GLIOMAS WITH PANOBINOSTAT". Neuro-Oncology 21, Supplement_6 (novembro de 2019): vi229. http://dx.doi.org/10.1093/neuonc/noz175.960.
Texto completo da fonteSumrall, Ashley Love, Joanne Xiu, Jennifer M. Eschbacher, Sandeep Mittal, Zoran Gatalica, Manjari K. Pandey, Surasak Phuphanich, Wolfgang Michael Korn, Gregory N. Fuller e Amy B. Heimberger. "Mutations of H3.3 and H3.1 in a large cohort of glioma tumors." Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): e13540-e13540. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e13540.
Texto completo da fonteArrillaga, Isabel, Sylvia Kurz, Ashley Sumrall, Nicholas A. Butowski, Rebecca A. Harrison, John Frederick De Groot, Nicole A. Shonka et al. "Single agent ONC201 in adult recurrent H3 K27M-mutant glioma." Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): 3005. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3005.
Texto completo da fonteAzadi, Amir, Ekokobe Fonkem e Tejas Ranade. "EPID-12. TREATMENT OUTCOMES OF MIDLINE GLIOMAS WITH H3K27 M: OUR BARROW NEUROLOGICAL INSTITUTE EXPERIENCE". Neuro-Oncology 22, Supplement_2 (novembro de 2020): ii81. http://dx.doi.org/10.1093/neuonc/noaa215.330.
Texto completo da fonteGardner, Sharon, Carl Koschmann, Rohinton Tarapore, Jeffrey Allen, Wafik Zaky, Yazmin Odia, Matthew Hall et al. "CTNI-36. SAFETY OF ONC201 ADMINISTERED TWO CONSECUTIVE DAYS PER WEEK IN PEDIATRIC H3 K27M-MUTANT GLIOMA PATIENTS". Neuro-Oncology 23, Supplement_6 (2 de novembro de 2021): vi67. http://dx.doi.org/10.1093/neuonc/noab196.261.
Texto completo da fonteDamodharan, Sudarshawn, Montserrat Lara-Velazquez, Brooke Carmen Williamsen, Jeffrey Helgager e Mahua Dey. "Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials". Journal of Personalized Medicine 12, n.º 5 (20 de maio de 2022): 840. http://dx.doi.org/10.3390/jpm12050840.
Texto completo da fonteGrebstad Tune, Benedicte, Heena Sareen, Branka Powter, Smadar Kahana-Edwin, Adam Cooper, Eng-Siew Koh, Cheok S. Lee et al. "From Pediatric to Adult Brain Cancer: Exploring Histone H3 Mutations in Australian Brain Cancer Patients". Biomedicines 11, n.º 11 (27 de outubro de 2023): 2907. http://dx.doi.org/10.3390/biomedicines11112907.
Texto completo da fonte